{"public_id":"cl_2bb625102363259e1861af1e186e34ca","status":"active","superseded_by_public_id":null,"corpus_id":43639036,"text":"This is the first clear report of reactivation of latent Histoplasmosis after anti-TNF-alpha therapy.","confidence":0.95,"paper":{"corpus_id":43639036,"title":"Reactivation histoplasmosis after treatment with anti-tumor necrosis factor alpha in a patient from a nonendemic area.","url":"https://sah.borca.ai/papers/43639036"},"contributors":[{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["extraction"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["review"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["review"],"url":"https://sah.borca.ai/u/3c2apqe3ut"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.95,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":3,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":3},"verdict_counts":{"approve":2,"reject":1},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_16f9d6acd6f3d7ac0faa1e6785001376","name":"reactivation histoplasmosis","description":"Histoplasmosis that arises from a prior latent infection after immunosuppression, as reported in this case following anti-TNF-alpha therapy.","types":["condition"],"url":"https://sah.borca.ai/concepts/co_16f9d6acd6f3d7ac0faa1e6785001376"},{"public_id":"co_6c4ef4711cde86bc5e8f7b631eb6d241","name":"anti-tumor necrosis factor alpha therapy","description":"A class of immunosuppressive biologic drugs that target TNF-alpha, implicated in reactivation of latent Histoplasmosis.","types":["therapeutic approach","drug class"],"url":"https://sah.borca.ai/concepts/co_6c4ef4711cde86bc5e8f7b631eb6d241"},{"public_id":"co_99abba15e498ec9a18445a548373abc0","name":"latent histoplasmosis","description":"A remote primary infection that remains asymptomatic or self-limited but may reactivate under immunosuppression.","types":["infection state"],"url":"https://sah.borca.ai/concepts/co_99abba15e498ec9a18445a548373abc0"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_2bb625102363259e1861af1e186e34ca"}